Expert Insight - Lung Cancer Genomic Testing Market
BIS Healthcare Analysts in conversation with: Shelly Pathak Technical Consultant Novogene, Europe
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick to read format.
The global lung cancer genomic testing market consists of numerous large-scale and small-scale manufacturers. With the rising awareness of oncology genetic biomarker testing and the increasing adoption of precision medicine in healthcare, the oncology molecular diagnostic manufacturers in the market have ample opportunities to expand their offerings.
The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The market growth can be primarily attributed to the increasing awareness and adoption of lung cancer genomic testing. The advancements targeted toward automating the tests, reducing turnaround time, improving specificity, and developing cost-effective tests are drivers for the global lung cancer genomic testing market.
BIS Healthcare Analysts in conversation with: Shelly Pathak Technical Consultant Novogene, Europe
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick to read format.
The global lung cancer genomic testing market consists of numerous large-scale and small-scale manufacturers. With the rising awareness of oncology genetic biomarker testing and the increasing adoption of precision medicine in healthcare, the oncology molecular diagnostic manufacturers in the market have ample opportunities to expand their offerings.
The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The market growth can be primarily attributed to the increasing awareness and adoption of lung cancer genomic testing. The advancements targeted toward automating the tests, reducing turnaround time, improving specificity, and developing cost-effective tests are drivers for the global lung cancer genomic testing market.